Psoriatic Arthritis

Risankizumab provides statistically greater improvements in signs and symptoms relative to placebo, and is well tolerated among patients with psoriatic arthritis, according to data presented at ACR Convergence 2021.

Among patients treated with TNF inhibitors, the risk for serious infection was “significantly lower” in those with psoriatic arthritis compared with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

Physical activity can lead to improved quality of life and self-reported function in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis, according to data published in Arthritis Care & Research.

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

Patients with psoriasis who use biologics are more likely to develop psoriatic arthritis than those on other or no therapies, according to retrospective data published in the Annals of the Rheumatic Diseases.

Diagnoses of arthritis, axial symptoms and tendonitis or enthesitis often increase over time before a patient is finally diagnosed with psoriatic arthritis, according to data published in Arthritis Research & Therapy.

The FDA has designated Cyltezo the first approved interchangeable biosimilar to treat certain inflammatory diseases, allowing pharmacists to substitute it for Humira without the need for the prescriber to alter the prescription.

Patients with psoriatic arthritis prefer oral over subcutaneous biologics, and prioritize complication avoidance and the ability to work and perform ordinary activities over clinical efficacy, according to data.

Ustekinumab, a biologic targeting cytokines interleukin 12 and 23, has been submitted for expanded approval in the treatment of juvenile psoriatic arthritis in pediatric patients aged 5 years and older, according to a press release.

Oligoarticular disease occurs in 47% of patients with psoriatic arthritis and presents similarly to polyarticular disease, often affecting small joints of the hands and feet, according to data published in The Journal of Rheumatology.